Abstract
Objective Knee osteoarthritis (OA) is a broadly applied diagnosis that may describe multiple subtypes of pain. The purpose of this study was to identify phenotypes of knee OA, using measures from the following pain-related domains: 1) knee OA pathology, 2) psychological distress, and 3) altered pain neurophysiology. Methods Data were selected from a total of 3,494 participants at visit 6 of the Osteoarthritis Initiative study. Latent class analysis was applied to the following variables: radiographic OA severity, quadriceps strength, body mass index, the Charlson Comorbidity Index (CCI), the Center for Epidemiologic Studies Depression Scale, the Coping Strategies Questionnaire-Catastrophizing subscale, number of bodily pain sites, and knee joint tenderness at 4 sites. The resulting classes were compared on the following demographic and clinical factors: age, sex, pain severity, disability, walking speed, and use of arthritis-related health care. Results A 4-class model was identified. Class 1 (4% of the study population) had higher CCI scores. Class 2 (24%) had higher knee joint sensitivity. Class 3 (10%) had greater psychological distress. Class 4 (62%) had lesser radiographic OA, little psychological involvement, greater strength, and less pain sensitivity. Additionally, class 1 was the oldest, on average. Class 4 was the youngest, had the lowest disability, and least pain. Class 3 had the worst disability and most pain. Conclusion Four distinct pain phenotypes of knee OA were identified. Psychological factors, comorbidity status, and joint sensitivity appear to be important in defining phenotypes of knee OA-related pain.
| Original language | English |
|---|---|
| Pages (from-to) | 612-620 |
| Number of pages | 9 |
| Journal | Arthritis Care and Research |
| Volume | 68 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2016 |
Funding
The Osteoarthritis Initiative is a public private partnership comprised of 5 contracts (N01 AR 2 2258, N01 AR 2 2259, N01 AR 2 2260, N01 AR 2 2261, and N01 AR 2 2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer. Private sector funding for the Osteoarthritis Initiative is managed by the Foundation for the NIH. Supported in part by the NIH (grants T32 AG000279 and R21 AG044710) and the Foundation for Physical Therapy (Promotion of Doctoral Studies I and II).
| Funders | Funder number |
|---|---|
| N01 AR 2 2260, N01 AR 2 2261, N01 AR 2 2259, N01 AR 2 2258, N01 AR 2 2262 | |
| R21AG044710 | |
| Pfizer | R21 AG044710, T32 AG000279 |
| GlaxoSmithKline | |
| Merck | |
Fingerprint
Dive into the research topics of 'Determination of Pain Phenotypes in Knee Osteoarthritis: A Latent Class Analysis Using Data from the Osteoarthritis Initiative'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver